ES2391375T3 - Nanoemulsiones de perfluorocarbono con superficie de potenciación de endocitosis para transferencia génica - Google Patents

Nanoemulsiones de perfluorocarbono con superficie de potenciación de endocitosis para transferencia génica Download PDF

Info

Publication number
ES2391375T3
ES2391375T3 ES09749747T ES09749747T ES2391375T3 ES 2391375 T3 ES2391375 T3 ES 2391375T3 ES 09749747 T ES09749747 T ES 09749747T ES 09749747 T ES09749747 T ES 09749747T ES 2391375 T3 ES2391375 T3 ES 2391375T3
Authority
ES
Spain
Prior art keywords
nanoemulsion
perfluorocarbon
component
endocytosis
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09749747T
Other languages
English (en)
Spanish (es)
Inventor
Sören Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soluventis GmbH
Original Assignee
Soluventis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluventis GmbH filed Critical Soluventis GmbH
Application granted granted Critical
Publication of ES2391375T3 publication Critical patent/ES2391375T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09749747T 2008-05-19 2009-05-13 Nanoemulsiones de perfluorocarbono con superficie de potenciación de endocitosis para transferencia génica Active ES2391375T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156434A EP2123256A1 (en) 2008-05-19 2008-05-19 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
EP08156434 2008-05-19
PCT/EP2009/055779 WO2009141257A1 (en) 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Publications (1)

Publication Number Publication Date
ES2391375T3 true ES2391375T3 (es) 2012-11-23

Family

ID=39869983

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09749747T Active ES2391375T3 (es) 2008-05-19 2009-05-13 Nanoemulsiones de perfluorocarbono con superficie de potenciación de endocitosis para transferencia génica
ES12171341.6T Active ES2642316T3 (es) 2008-05-19 2009-05-13 Nanoemulsiones de perfluorocarbono con superficie de potenciación de la endocitosis para transferencia génica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12171341.6T Active ES2642316T3 (es) 2008-05-19 2009-05-13 Nanoemulsiones de perfluorocarbono con superficie de potenciación de la endocitosis para transferencia génica

Country Status (14)

Country Link
US (1) US9616131B2 (enExample)
EP (3) EP2123256A1 (enExample)
JP (1) JP5546534B2 (enExample)
CN (2) CN102847170B (enExample)
AU (1) AU2009249812B2 (enExample)
CA (1) CA2725513C (enExample)
DK (2) DK2510921T3 (enExample)
ES (2) ES2391375T3 (enExample)
HU (1) HUE035320T2 (enExample)
IL (1) IL209205A (enExample)
NZ (1) NZ589417A (enExample)
PL (2) PL2285349T3 (enExample)
WO (1) WO2009141257A1 (enExample)
ZA (1) ZA201008274B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
CN103764169B (zh) * 2011-03-31 2017-06-13 康斯坦策·沙费尔 用于非病毒转移核酸的全氟化化合物
CN103251980B (zh) * 2013-05-17 2014-07-02 中国人民解放军第四军医大学 全氟三丁胺与纤维蛋白水凝胶复合的神经导管制备方法
CN103263695B (zh) * 2013-05-17 2014-10-29 中国人民解放军第四军医大学 全氟三乙胺乳液与种子细胞复合的神经导管制备方法
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
EP3549609A4 (en) * 2016-12-01 2020-07-29 Saitama University ENDOCYTOSIS ACTIVATOR FOR DRUG DELIVERY SYSTEMS
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6050578B2 (ja) 1981-12-25 1985-11-09 日本スチレンペ−パ−株式会社 合成樹脂発泡体の製造法
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP0833608A2 (en) * 1995-06-07 1998-04-08 Alliance Pharmaceutical Corporation Reverse fluorocarbon emulsion compositions for drug delivery
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
JP2001002592A (ja) * 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
KR20080046750A (ko) 2000-03-24 2008-05-27 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
KR20030039363A (ko) * 2000-07-20 2003-05-17 오뜨끄리또에 악찌오네르노에 오브셰스뜨보 나우취노-쁘로이즈보드스뜨벤나야 피르마 "뻬르프또란" 의료용 퍼플루오르 유기화합물의 유제 및 그 제조방법 및그것을 이용한 질병 치료 및 예방방법
ATE392812T1 (de) 2001-07-10 2008-05-15 Sonogene Llc Verbesserung der transfektion von dna in die leber
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Also Published As

Publication number Publication date
AU2009249812B2 (en) 2013-08-22
CN102112109B (zh) 2016-10-12
CN102847170B (zh) 2016-03-16
EP2510921B1 (en) 2017-07-12
HK1159479A1 (zh) 2012-08-03
DK2285349T3 (da) 2012-10-22
CN102847170A (zh) 2013-01-02
EP2285349A1 (en) 2011-02-23
CA2725513C (en) 2013-07-02
WO2009141257A1 (en) 2009-11-26
US9616131B2 (en) 2017-04-11
PL2285349T3 (pl) 2012-12-31
DK2510921T3 (en) 2017-10-23
CN102112109A (zh) 2011-06-29
AU2009249812A1 (en) 2009-11-26
EP2510921A1 (en) 2012-10-17
NZ589417A (en) 2012-03-30
HK1179533A1 (zh) 2013-10-04
IL209205A (en) 2015-08-31
CA2725513A1 (en) 2009-11-26
HUE035320T2 (en) 2018-05-02
EP2123256A1 (en) 2009-11-25
EP2285349B1 (en) 2012-07-11
IL209205A0 (en) 2011-01-31
ES2642316T3 (es) 2017-11-16
JP2011520936A (ja) 2011-07-21
US20110091561A1 (en) 2011-04-21
JP5546534B2 (ja) 2014-07-09
ZA201008274B (en) 2012-02-29
PL2510921T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
ES2391375T3 (es) Nanoemulsiones de perfluorocarbono con superficie de potenciación de endocitosis para transferencia génica
ES2564185T3 (es) Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
CN102170866B (zh) 亲脂性或两亲性治疗剂在纳米乳剂中的包囊
TWI269652B (en) Transnasal anticonvulsive compositions and modulated process
JP2008520600A (ja) 局所投与のための医薬組成物におけるまたはそれに関する改善
TW201124425A (en) Parenteral formulations of gemcitabine derivatives
RS55530B1 (sr) So fotosenzitivnog agensa za upotrebu u fotohemijskoj internalizaciji
Guo et al. Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy
KR20220092363A (ko) 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물
Vasylaki et al. Targeting the kidneys at the nanoscale: nanotechnology in nephrology
JP2010209012A (ja) ｐＨ応答性リポソーム
Siqueira Leite et al. Microemulsions as platforms for transdermal delivery of hydrophilic drugs-a review
Deshmukh et al. Vesicular carriers for direct nose-to-brain drug delivery
CN117338948A (zh) 一种ace2特异性结合肽修饰的递药系统及其制备方法和应用
HK1159479B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
WO2018124423A1 (ko) 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법
CN117241836A (zh) 包含脂质纳米颗粒的用于预防或治疗癌症的组合物
HK1179533B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
BR102017016440A2 (pt) Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
EP4268851A1 (en) Composition for preventing or treating cancer, containing lipid nanoparticles
Boloix Amenós et al. Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics
Huang Functionalized Lipid Nanoparticles Show Efficacy in Glioma Animal Models
WO2023054241A1 (ja) 核酸を脳組織に送達するために用いられる脂質ナノ粒子